Frank I Lin1,2, E M Gonzalez3, S Kummar4, K Do4, J Shih5, S Adler6, K A Kurdziel3, A Ton3, B Turkbey3, P M Jacobs7, S Bhattacharyya8, A P Chen9, J M Collins4, J H Doroshow4, P L Choyke3, M L Lindenberg3. 1. Cancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. frank.lin2@nih.gov. 2. Molecular Imaging Program, National Cancer Institute, Bethesda, MD, USA. frank.lin2@nih.gov. 3. Molecular Imaging Program, National Cancer Institute, Bethesda, MD, USA. 4. Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. 5. Biometric Research Program, National Cancer Institute, NIH, Bethesda, MD, USA. 6. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, 21702, USA. 7. Cancer Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. 8. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA. 9. Early Clinical Trials Development Program, DCTD, National Cancer Institute, Bethesda, MD, USA.
Abstract
BACKGROUND: Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen. METHODS: Fifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with 18F-FES PET at baseline. Eight had positive lesions on the baseline scan and underwent follow-up imaging with 18F-FES 1-5 days post administration of Z-endoxifen. RESULTS: Statistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration. CONCLUSION: F-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.
BACKGROUND:Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen. METHODS: Fifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with 18F-FES PET at baseline. Eight had positive lesions on the baseline scan and underwent follow-up imaging with 18F-FES 1-5 days post administration of Z-endoxifen. RESULTS: Statistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration. CONCLUSION: F-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.
Authors: Lanell M Peterson; Brenda F Kurland; Jeanne M Link; Erin K Schubert; Svetlana Stekhova; Hannah M Linden; David A Mankoff Journal: Nucl Med Biol Date: 2011-05-05 Impact factor: 2.408
Authors: Michel van Kruchten; Geke A P Hospers; Andor W J M Glaudemans; Harry Hollema; Henriëtte J G Arts; Anna K L Reyners Journal: Eur J Cancer Date: 2013-09-02 Impact factor: 9.162
Authors: J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: Bernd J Krause; Michael Souvatzoglou; Ken Herrmann; Axel W Weber; Tibor Schuster; Andreas K Buck; Roman Nawroth; Gregor Weirich; Uwe Treiber; Hans-Jürgen Wester; Sibylle I Ziegler; Reingard Senekowitsch-Schmidtke; Markus Schwaiger Journal: Eur J Nucl Med Mol Imaging Date: 2010-05-30 Impact factor: 9.236
Authors: Michel van Kruchten; Erik F J de Vries; Henriette J G Arts; Neeltina M Jager; Alphons H H Bongaerts; Andor W J M Glaudemans; Harry Hollema; Elisabeth G E de Vries; Geke A P Hospers; Anna K L Reyners Journal: J Nucl Med Date: 2014-12-04 Impact factor: 10.057
Authors: Pedram Heidari; Francis Deng; Shadi A Esfahani; Alicia K Leece; Timothy M Shoup; Neil Vasdev; Umar Mahmood Journal: Clin Cancer Res Date: 2015-01-21 Impact factor: 12.531
Authors: Amy M Fowler; Amy S Clark; John A Katzenellenbogen; Hannah M Linden; Farrokh Dehdashti Journal: J Nucl Med Date: 2016-02 Impact factor: 10.057
Authors: Mary L Gemignani; Sujata Patil; Venkatraman E Seshan; Michelle Sampson; John L Humm; Jason S Lewis; Edi Brogi; Steven M Larson; Monica Morrow; Neeta Pandit-Taskar Journal: J Nucl Med Date: 2013-08-22 Impact factor: 10.057
Authors: Michel van Kruchten; Andor W J M Glaudemans; Erik F J de Vries; Carolien P Schröder; Elisabeth G E de Vries; Geke A P Hospers Journal: Eur J Nucl Med Mol Imaging Date: 2015-06-20 Impact factor: 9.236
Authors: Naoko Takebe; Geraldine O'Sullivan Coyne; Shivaani Kummar; Jerry Collins; Joel M Reid; Richard Piekarz; Nancy Moore; Lamin Juwara; Barry C Johnson; Rachel Bishop; Frank I Lin; Esther Mena; Peter L Choyke; M Liza Lindenberg; Larry V Rubinstein; Cecilia Monge Bonilla; Matthew P Goetz; Matthew M Ames; Renee M McGovern; Howard Streicher; Joseph M Covey; James H Doroshow; Alice P Chen Journal: Oncotarget Date: 2021-02-16
Authors: Brenda F Kurland; Jay R Wiggins; Amandine Coche; Charlotte Fontan; Yann Bouvet; Peter Webner; Chaitanya Divgi; Hannah M Linden Journal: Oncologist Date: 2020-05-15 Impact factor: 5.837
Authors: Imke H Bartelink; Ella F Jones; Sheerin K Shahidi-Latham; Pei Rong Evelyn Lee; Yanan Zheng; Paolo Vicini; Laura van 't Veer; Denise Wolf; Andrei Iagaru; Deanna L Kroetz; Brendan Prideaux; Cornelius Cilliers; Greg M Thurber; Zena Wimana; Geraldine Gebhart Journal: Clin Pharmacol Ther Date: 2018-10-06 Impact factor: 6.875